Bio-Path Holdings to Present at the 28th Annual ROTH Conference on Monday, March 14 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) BPTH_ROTH_Conf_20160307
Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia BPTH BP1001_cohort_8_completion
Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting BPTH ASH 2015_PR
Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting BPTH_ASH_PR2015
Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia BPTH_Cohort_7_complete
Bio-Path Holdings To Present at the 17th Annual Rodman & Renshaw Global Investment Conference BPTH_Rodman_Renshaw2015
Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers BPTH_SAB_Announcement
